Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 3, 2008

Raven and Emory University Scientist Team Up for Prostate Cancer Stem Cell Research

  • Raven biotechnologies and a researcher at Emory University Medical School entered a cancer stem cell research collaboration. With the focus on prostate cancer, the partners will also assess the development of diagnostic and prognostic tests.

    Leland W.K. Chung, Ph.D., director of the molecular urology and therapeutics program at the Emory University Medical School’s department of urology will have access to Raven’s prostate cancer stem cells. Dr. Chung and the company will examine prostate cancer biology, disease progression, and subsequent metastasis.

    Raven will also provide Emory with a library of antibodies targeting cancer stem cells to study their use as prognostic devices and to monitor treatment.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »